Biology Reference
In-Depth Information
22. Rose-John S, Schooltink H (2007) Cytokines
are a therapeutic target for the prevention of
inflammation-induced cancers. Recent Results
Cancer Res 174:57-66
23. Grotzinger J et al (1999) IL-6 type cytokine
receptor complexes: hexamer, tetramer or
both? Biol Chem 380:803-813
24. Grotzinger J et al (1997) The family of the
IL-6-type cytokines: specificity and promiscu-
ity of the receptor complexes. Proteins
27:96-109
25. Fischer M et al (1997) I. A bioactive designer
cytokine for human hematopoietic progenitor
cell expansion. Nat Biotechnol 15:142-145
26. Galun E et al (2000) Liver regeneration
induced by a designer human IL-6/sIL-6R
fusion protein reverses severe hepatocellular
injury. FASEB J 14:1979-1987
27. Peters M et al (2000) Combined interleukin 6
and soluble interleukin 6 receptor accelerates
murine liver regeneration. Gastroenterology
119:1663-1671
28. Marz P et al (1998) Sympathetic neurons can
produce and respond to interleukin 6. Proc
Natl Acad Sci U S A 95:3251-3256
29. Marz P et al (1999) Neural activities of IL-6-
type cytokines often depend on soluble
cytokine
ment from embryonic stem cells. Stem Cells
Dev 21:121-132
37. Hacker C et al (2003) Transcriptional profiling
identifies Id2 function in dendritic cell devel-
opment. Nat Immunol 4:380-386
38. Sere KM et al (2011) Dendritic cell lineage
commitment is instructed by distinct cytokine
signals. Eur J Cell Biol 91:515-523
39. Humphrey RK et al (2004) Maintenance of
pluripotency in human embryonic stem cells
is
STAT3
independent.
Stem
Cells
22:522-530
40. Viswanathan S et al (2002) Ligand/receptor
signaling threshold (LIST) model accounts
for gp130-mediated embryonic stem cell self-
renewal responses to LIF and HIL-6. Stem
Cells 20:119-138
41. Jostock T et al (2001) Soluble gp130 is the
natural inhibitor of soluble interleukin-6
receptor transsignaling responses. Eur J
Biochem 268:160-167
42. Nowell MA et al (2003) Soluble IL-6 receptor
governs IL-6 activity in experimental arthritis:
blockade of arthritis severity by soluble glyco-
protein 130. J Immunol 171:3202-3209
43. Nowell MA et al (2009) Therapeutic target-
ing of IL-6 trans signaling counteracts STAT3
control of experimental inflammatory arthri-
tis. J Immunol 182:613-622
44. Richards PJ et al (2006) Functional character-
ization of a soluble gp130 isoform and its
therapeutic capacity in an experimental model
of inflammatory arthritis. Arthritis Rheum
54:1662-1672
45. Hurst SM et al (2001) Il-6 and its soluble
receptor orchestrate a temporal switch in the
pattern of leukocyte recruitment seen during
acute inflammation. Immunity 14:705-714
46. Barkhausen T et al (2011) Selective blockade
of interleukin-6 trans-signaling improves sur-
vival in a murine polymicrobial sepsis model.
Crit Care Med 39:1407-1413
47. Greenhill CJ et al (2011) IL-6 trans-signaling
modulates TLR4-dependent inflammatory
responses
receptors.
Eur
J
Neurosci
11:2995-3004
30. Islam O et al (2009) Interleukin-6 and neural
stem cells: more than gliogenesis. Mol Biol
Cell 20:188-199
31. Klouche M et al (1999) Novel path to activation
of vascular smooth muscle cells: up-regulation
of gp130 creates an autocrine activation loop by
IL-6 and its soluble receptor. J Immunol
163:4583-4589
32. Audet J et al (2001) Distinct role of gp130
activation in promoting self-renewal divisions
by mitogenically stimulated murine
hematopoietic stem cells. Proc Natl Acad Sci
U S A 98:1757-1762
33. Baiocchi M et al (2000) An IL-6/IL-6 solu-
ble receptor (IL-6R) hybrid protein (H-IL-6)
induces EPO-independent erythroid differen-
tiation in human CD34(+) cells. Cytokine
12:1395-1399
34. Hieronymus T et al (2008) The transcription
factor repertoire of Flt3+ hematopoietic stem
cells. Cells Tissues Organs 188:103-115
35. Hieronymus T et al (2005) Progressive and
controlled development of mouse dendritic
cells from Flt3+CD11b+ progenitors in vitro.
J Immunol 174:2552-2562
36. Ding X et al (2012) Polycomb group protein
bmi1 promotes hematopoietic cell develop-
via
STAT3.
J
Immunol
186:1199-1208
48. Atreya R et al (2000) Blockade of interleukin
6 trans signaling suppresses T-cell resistance
against apoptosis in chronic intestinal
inflammation: evidence in crohn disease and
experimental colitis in vivo. Nat Med
6:583-588
49. Mitsuyama K et al (2006) STAT3 activation
via interleukin 6 trans-signalling contributes
to ileitis in SAMP1/Yit mice. Gut 55:
1263-1269
Search WWH ::
Custom Search